Analyst consensus rating
Outlook Therapeutics Analyst Rating: none
Direct answer
Outlook Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.90.
Forecast evidence checked September 3, 2026.
Get free Outlook Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.65
- Average price target
- $4.90
- High price target
- $10.00
- Low price target
- $1.60
- Low target gap
- +146.5%
- Target upside
- +655%
- High target gap
- +1,440.8%
- Target range width
- 1,294.3%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 3, 2026
- Valid through
- September 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Outlook Therapeutics?
Outlook Therapeutics has a verified none consensus. The same dataset has an average price target of $4.90.
How far are Outlook Therapeutics's low and high targets from the recorded price?
The low target implies +146.5%, while the high target implies +1,440.8%.
How many analysts are included in Outlook Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Outlook Therapeutics's target upside or downside calculated?
The average target of $4.90 is divided by the recorded price of $0.65, then one is subtracted to produce +655%. This does not guarantee a future return.
When was Outlook Therapeutics's analyst forecast verified?
The data was verified on 2026-09-03. The dataset is valid through 2026-09-10.